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A B S T R A C T
Action myoclonus-renal failure syndrome (AMRF) is considered a rare form of progressive myoclonus
epilepsy (PME) associated with renal failure. A mutation on the gene encoding the lysosomal integral
membrane protein type 2-LIMP-2 (SCARB2), the receptor responsible for targeting glucocerebrosidase to
the lysosomes, was recently described, allowing a better understanding of its etiopathogenesis.
We describe clinically two sisters with AMRF that resulted from a mutation in the SCARB2 gene. The
renal involvement was due to nephropathy C1q. When substrate-reduction therapy, to correct the
possible glucocerebroside storage in the cells with glucocerebrosidase deﬁciency, was administered to
one of the siblings, a signiﬁcant improvement was observed. This report points out a rational for a
therapeutical approach to this new lysossomopathy.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Action myoclonus-renal failure syndrome (AMRF) is considered
a rare form of progressive myoclonic epilepsy (PME) associated
with renal dysfunction. It was ﬁrst described by Andermann in
19861 and it was initially believed to be conﬁned to French
Canadians. Nowadays it is recognized as having a more extensive
ethnic and geographic distribution including German, Cuban,
Australian American and Portuguese patients.2–4 Mutations in
lysosomal integral membrane protein type 2 (LIMP-2) gene
(SCARB2) were recently associated with AMRF by two independent
studies.3,4 We report the clinical features of two siblings with PME
and nephrotic syndrome whose genetic alteration in SCARB2 gene
was previously described by Balreira in 2008.3 LIMP-2 is
considered a sorting receptor for the lysosomal hidrolase b-
glucocerebrosidase (GCase),5 the enzyme that is deﬁcient in the
majority of Gaucher’s disease (GD) patients.6 These patients
present a cell type speciﬁc deﬁciency of GCase (normal activity in
leukocytes and deﬁcient activity in cultured skin ﬁbroblasts)
without any alteration in the gene encoding for GCase (GBA gene).3
The hypothesis of glucosylceramide storage in central and/or
peripheral nervous system, as a consequence of the secondary* Corresponding author at: Department of Neurology, Hospital Santo Anto´nio,
Largo Prof. Abel Salazar, 4099-001 Porto, Portugal. Tel.: +351 939322333.
E-mail address: joaomchaves71@hotmail.com (J. Chaves).
1059-1311/$ – see front matter  2011 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2011.06.018biochemical defect was raised. In order to try to overcome the
pathologic effect of the glycosphingolipids storage, substrate
reduction therapy (SRT) with Miglustat1, the inhibitor of
glucosylceramide synthesis, was assayed in one patient. This
paper presents a detailed clinical report of these two siblings and
the results obtained with the experimental STR.
2. Case report
Two female siblings, from a northern Portuguese family are
described. The parents were consanguineous and an older sister
was healthy.
Patient 1 started having myoclonic jerks during active move-
ments of the upper limbs at the age of 15, with insidious
progression of intensity and extension to the lower limbs and
trunk, which led to gait instability. Slow horizontal saccadic eye
movements were observed at the age of 18. At 20, she was totally
dependent, unable to write, to eat independently, to walk and
presented a blurred speech with swallowing difﬁculties. When the
patient was 21, she began having edemas in both lower limbs that
became generalised with bilateral pleural effusions. Blood pressure
was always within the normal range. An increase in body
temperature, predominantly in the evening, was observed even
in the absence of evidence of systemic infections. She was treated
with valproic acid (maximum dose 3900 mg/day), clonazepam
(maximum dose 8 mg/day), and piracetam (maximum dose 48 mg/
day). A slight but transient reduction of myoclonus was observedvier Ltd. All rights reserved.
Fig. 2. Deposition of IgM (IF).
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started enzymatic replacement therapy (ERT) with Imiglucerase1,
60 U/Kg every two weeks for a year, without improvement. No
cognitive decline was observed. She died of septicemia with
multiorgan failure at the age of 23.
Patient 2 started with the same type of symptoms when she
was 17 years old and the same pattern of progression was
documented. She had generalised hyperhidrosis. Similar to her
sister, she presented slow horizontal saccades at the age of 20. She
became totally dependent and presented edemas at the age of 22.
Blood pressure was also always within normal limits. A
hyperthermia predominantly in the evening not related to
systemic infections was also registered. She was treated with
valproic acid (maximum dose 3500 mg/day), clonazepam (maxi-
mum dose 12 mg/day), phenobarbitone (maximum dose 300 mg/
day), topiramate (maximum dose 500 mg/day), piracetam (maxi-
mum dose 36 mg/day), and levetiracetam (maximum dose
3000 mg/day) with initial but transient beneﬁt. At the age 21,
she started ERT with Imiglucerase1, 60 U/kg every two weeks for a
year with no improvement. At the age of 24, she began SRT with
Miglustat1 (600 mg/daily). At this stage she was completely
dependent; had instability of the limbs and trunk due to myoclonic
jerks; was unable to seat in the wheelchair; a nasogastric tube was
used for feeding; and had anarthria. With SRT, there was a
signiﬁcant reduction on myoclonic jerks and the nasogastric tube
was removed. She regained the capacity to seat and eat orally. An
improvement in speech was also observed, she was able to produce
words again. No intellectual impairment was detected. Despite the
continuous and sustained clinical improvement observed for
almost 2 years, she died of pneumonia at the age of 26.
3. Investigation
Patients’ brain MRI was normal. The routine EEG showed
normal background with generalized paroxysms of spike and
polispikes and waves mainly in the posterior regions with the eyes
closed during intermittent photostimulation. A giant potential was
obtained in somatosensory evoked potential in patient 2.
Toracic, abdominopelvic CT and transthoracic echocardiogram
were normal. Renovesical ultrasonographies were normal includ-
ing the size of kidneys.
At the age of 18, proteinuria of 1 g/24 h was detected in patient
1. When she was 21, she developed normocytic normochromic
anemia, thrombocytopenia, hypoalbuminemia and nephrotic
proteinuria. At 18, patient 2 developed proteinuria that becameFig. 1. Deposition of C1q (IF).nephrotic at 21. At 23, patient 2 developed normocytic normo-
chromic anemia without thrombocytopenia and hypoalbumine-
mia. At the age of 24, since she was treated with SRT, her renal
function was always normal and proteinuria levels did not
increase.
Lipids, renal, hepatic function and coagulation tests were
normal. In a series of immunological studies only an increase in
acute phase proteins and the presence of circulating immuno-
complexes were observed. The cellular immunophenotype (T, B
and NK populations) in peripheral blood and platelet function
studies were normal.
Patient 1 underwent a renal biopsy. Light microscopy study
revealed extensive tubular abnormalities with isometric vacuoli-
zation in distal and collecting tubules, presence of granular
material in cortical tubules without inﬂammatory inﬁltration
deposits and absence of Gaucher cells. No glomeruli were observed
due to technical reasons. Immunoﬂuorescence microscopy (IF)
showed a marked deposition of C1q (Fig. 1), IgM (Fig. 2), and
irregular moderated deposits of C3 (Fig. 3) in capillary loops.
Patient 1 underwent a bone marrow biopsy which was normal
with absence of Gaucher cells.
Light and ultrastructural studies of skin biopsy were normal.
Muscle biopsy was normal with normal activity of the analysed
mitochondrial enzymes. Cariotype was normal. There was noFig. 3. Deposition of C3 (IF).
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with Ragged Red Fibers mutations A8344G and T8356C were not
found. The most common genetic mutations for Unverricht-
Lundborg disease were also excluded.
Patients’ serum lactate, pyruvate, urinary oligosaccharides,
arilsulfatase A, total b-hexosaminidase, b-hexosaminidase A, b-
galactosidase and a-neuraminidase activity determined in cul-
tured ﬁbroblasts were normal. GCase in cultured skin ﬁbroblasts
was deﬁcient (about 10% of controls mean) with a normal activity
in leukocytes. Plasmatic acid phosphatase and chitotriosidase
activities were normal. No mutations in GBA gene were found but
when SCARB2 gene was analysed, a nonsense mutation was
identiﬁed. Further investigation showed that besides lacking
immunodectectable LIMP-2, patients’ ﬁbroblasts had also mis-
located and decreased amounts of GCase.3
4. Discussion
We describe two siblings with LIMP-2 deﬁciency due to a
homozygous mutation on SCARB2 gene, whose deﬁciency was
recently established as responsible for AMRF.3,4 LIMP-2 is the
speciﬁc binding partner of GCase, the enzyme defective in GD.
LIMP-2 was proposed to bind GCase in the endoplasmic reticulum
and to escort the enzyme to late endosomes/lysosomes, where
dissociation occurs.5
The deﬁcient GCase activity in patients ﬁbroblasts led us to
suspect initially of a juvenile neuronopathic form of GD, however
in contrast with GD patients, GCase activity in leukocytes was
normal, the activity of plasmatic chitotriosidase was not increased,
our patients did not have visceromegaly or cognitive decline and
did not have ‘‘Gaucher cells’’ in kidney and bone marrow biopsies.
No kidney visible storage was detected. In our case, renal
involvement was due to a C1q nephropathy, which can be
presented as focal segmental sclerosis in light microscopy.7 In
fact, Badhwar2 described a collapsing glomerulopathy with focal
glomeruloclerosis in AMRF syndrome. Unfortunately, no glomeruli
were present in sections for light microscopy analysis. C1q
nephropathy is a peculiar form of glomerulonephritis character-
ized by mesangial immunoglobulin and complement deposits,
predominantly C1q, with no evidence of systemic lupus erythe-
matosus. C1q nephropathy is a rare condition associated with a
wide spectrum of diseases. It remains unclear whether the
deposition of C1q in the glomeruli is the response to the deposition
of immunoglobulin or immune complex, or whether deposition is a
non-speciﬁc trapping that accompanies increased glomerular
protein trafﬁcking associated with proteinuria. Not only the
pathogenesis of C1q deposition in glomeruli, but also its
signiﬁcance are still uncertain.8 A very different renal involvement
has been described in LIMP-2 deﬁcient mice, with dilatation of the
renal pelvis and calyces due to massive accumulation of vesicular
structures of lysosomal origin which causes obstruction of the
urinary tract that leads to hydronephrosis.9 There are recent
reports of patients with PME due to SCARB2 mutation but without
any evidence of renal failure.10
The identiﬁcation of the mutation in the gene encoding LIMP-2
and the mechanism involved in this novel lysosomal disorder maysupport why ERT with recombinant GlcCerase (Cerezyme1) was
unsuitable to our patients. However, despite of SRT (Miglustat1)
was initiated in patient 2 in a very late stage of the disease, a
signiﬁcant and sustained clinical improvement was observed. SRT
aims to reduce the rate of glycosphingolipid biosynthesis in order
to decrease the amounts of glycosphingolipid storage. It consists of
oral administration of N-butyldeoxynojirimycin (NB-DNJ). NB-DNJ
are iminosugars extracted from plants and microorganisms, that
inhibit the enzyme glucosylceramide synthase (E.C. 2.4.1.80),
which catalyzes the ﬁrst step in GSL biosynthesis: the transfer of
glucose from UDP-glucose to ceramide to form glucosylceramide
(Platt, 2001). NB-DNJ are small molecules with capacity to cross
the blood brain barrier and with potential to be effective in
lysosomal storage disorders with neurological involvement. There
are reports of improvements of neurological manifestations in GD
type III patient11 and Nieman Pick type C.12
Our clinical data suggest that STR seems to improve the quality
of life of these patients, and we believe it ought to be tried in the
early stages of the disease. However, more studies are needed to
prove the efﬁcacy of this therapy in LIMP-2 deﬁcient patients with
secondary deﬁciency in glucocerebrosidase. This new lysosomal
storage disease with SCARB2/LIMP-2 mutation must be considered
in every patient with PME without cognitive decline with or
without renal involvement in which a cause cannot be identiﬁed.
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